Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:16:52.967Z.
Consensus retrieved: 2026-10-06T11:56:34.860Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:16:52.967Z.
Quote observation: 2026-10-06T14:15:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8ce36116f6c4cf8d6fa5d70ec9ce1d9cbc86489a03ebd5e18b87b9f8ced35068
Forward PE Ratio (N/A) = Dated Quote Price ($21.68) / Consensus Forward EPS ($-1.19)
FORWARD PE RATIO
N/A
GH Research PLC
Market Cap
$1.49B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GH Research PLC (GHRS) | $1.49B | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 50.08 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 17.80 |
| Certara, Inc. (CERT)vs › | $1.52B | 28.76 |
| Innoviva, Inc. (INVA)vs › | $1.53B | 8.59 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.35B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $21.68, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.19 | $-1.40 – $-1.09 | 7 | n/m |
| 2027-12-31 | $-1.83 | $-2.33 – $-1.39 | 7 | n/m |
| 2028-12-31 | $-1.99 | $-2.90 – $-1.56 | 8 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
